Skip to main content
KMDA
NASDAQ Life Sciences

Kamada Projects Strong Double-Digit Revenue and EBITDA Growth for 2026

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$7.78
Mkt Cap
$428.574M
52W Low
$5.54
52W High
$9.155
52W Position info
40% above low
Off High info
15% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

KMDA sits 40% above its 52-week low of $5.54.

Summary

Kamada Ltd. announced optimistic 2026 financial guidance, projecting double-digit revenue and adjusted EBITDA growth driven by organic expansion, while also affirming its 2025 targets.


Key Events · Earnings and Guidance · KMDA

  • 2026 Financial Guidance

    Kamada forecasts 2026 revenues between $200 million and $205 million, and adjusted EBITDA between $50 million and $53 million.

  • Double-Digit Organic Growth

    The 2026 guidance represents a year-over-year increase of 13% in revenues and 23% in adjusted EBITDA (mid-point basis), based solely on continued organic growth.

  • 2025 Guidance Affirmed

    The company reaffirmed its 2025 financial guidance of $178 million - $182 million in revenues and $40 million - $44 million of adjusted EBITDA, with approximately $75 million in year-end cash.

  • Strategic Expansion

    Growth is expected from expanding the commercial product portfolio, launching biosimilars, extending distribution to the MENA region, and increasing plasma collection.


Analysis · KMDA · Life Sciences

Kamada Ltd. has provided robust financial guidance for 2026, forecasting significant double-digit increases in both revenues and adjusted EBITDA, driven by organic growth. This positive outlook, coupled with the affirmation of its 2025 financial targets and a healthy cash position, signals strong operational performance and strategic execution. The company's ability to project continued growth despite a reduction in GLASSIA royalty payments highlights the strength and diversification of its commercial product portfolio and plasma collection operations. Investors should view this guidance as a strong indicator of future profitability and market expansion.

At the time of this filing, KMDA was trading at $7.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $428.6M. The 52-week trading range was $5.54 to $9.16. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

KMDA - Latest Insights

KMDA
Jul 20, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $6.91
Real-time Price: $7.06 info
Change: +$0.150 (+2%) info
Market Cap: $407.322M info
KMDA
Jul 20, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.43
Real-time Price: $7.06 info
Change: -$0.370 (-5%) info
Market Cap: $407.322M info
KMDA
Jul 13, 2026, 7:46 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $7.12
Real-time Price: $7.06 info
Change: -$0.060 (-0.84%) info
Market Cap: $407.322M info
KMDA
Jun 01, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $7.91
Real-time Price: $7.06 info
Change: -$0.850 (-11%) info
Market Cap: $407.322M info
KMDA
Jun 01, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.99
Real-time Price: $7.06 info
Change: -$0.930 (-12%) info
Market Cap: $407.322M info